NCT01198665 - RAD001 Combined With CHOP in Newly Diagnosed Peripheral T-cell Lymphomas | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 31, 2010

Primary Completion Date

December 31, 2014

Study Completion Date

December 31, 2014

Conditions

Peripheral T Cell Lymphoma UnspecifiedAnaplastic Large Cell Lymphoma, ALK-negativeAngioimmunoblastic T Cell LymphomaCutaneous T Cell Lymphoma

Interventions

DRUG

RAD001 (Everolimus)

Phase I Level 1: RAD001 2.5 mg PO daily D1-14 + CHOP Level 2: RAD001 5 mg PO daily D1-14 + CHOP Level 3: RAD001 7.5 mg PO daily D1-14 + CHOP Level 4: RAD001 10 mg PO daily D1-14 + CHOP CHOP every 3 weeks D1 Cytoxan 750mg/m2 + D5W 100ml MIV over 1hr D1 Doxorubicin 50mg/m2 + D5W 100ml MIV over 30mins D1 Vincristine 1.4mg/m2 (max.2mg) IV push D1-D5 Prednisolone 100mg/d PO (40-30-30) Phase II Determined dosage of RAD001 + CHOP every 3 weeks

Trial Locations (5)

135710

Samsung Medical Center, Seoul

Unknown

National Cancer Center, Goyang-si

Asan Medical Center, Seoul

Korea Cancer Center Hospital, Seoul

Yonsei Medical Center, Severance Hospital, Seoul